Tech Company Financing Transactions
Beam Therapeutics Funding Round
On 3/7/2019, Beam Therapeutics raised $135 million in Series B investment from Altitude Life Science Ventures, Arch Venture Partners and Cormorant Asset Management.
Transaction Overview
Company Name
Announced On
3/7/2019
Transaction Type
Venture Equity
Amount
$135,000,000
Round
Series B
Investors
Proceeds Purpose
Proceeds from the financing will be used to advance the company's development of next-generation CRISPR technologies, expand its pipeline of base editing programs, and further extend its scientific and technical leadership.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
26 Landsdowne St. 2nd Floor
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Overview
Beam Therapeutics is pioneering the use of CRISPR base editing to develop precision genetic medicines that treat disease, one letter at a time.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Evans
Chief Scientific Officer
Giuseppe Ciaramella
Co-Founder
Keith Joung
Co-Founder
David Liu
Co-Founder
Feng Zhang
Vice President
Francine Gregoire
Vice President
Dana Levasseur
VP - Bus. Development
Courtney Wallace
VP - Finance
Suzanne Fleming
Browse more venture capital transactions:
Prev: 3/7/2019: WadeandWendy venture capital transaction
Next: 3/8/2019: Jargon venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs